NZ588179A - Antiviral therapeutic agents comprising fused tricyclic compounds comprising a pyrrolo[1.2-f][1,2,4]triazine moiety - Google Patents

Antiviral therapeutic agents comprising fused tricyclic compounds comprising a pyrrolo[1.2-f][1,2,4]triazine moiety

Info

Publication number
NZ588179A
NZ588179A NZ588179A NZ58817909A NZ588179A NZ 588179 A NZ588179 A NZ 588179A NZ 588179 A NZ588179 A NZ 588179A NZ 58817909 A NZ58817909 A NZ 58817909A NZ 588179 A NZ588179 A NZ 588179A
Authority
NZ
New Zealand
Prior art keywords
pyrrolo
therapeutic agents
compounds
tricyclic compounds
fused tricyclic
Prior art date
Application number
NZ588179A
Other languages
English (en)
Inventor
Yarlagadda S Babu
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of NZ588179A publication Critical patent/NZ588179A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99Enzyme inactivation by chemical treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02TCLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO TRANSPORTATION
    • Y02T10/00Road transport of goods or passengers
    • Y02T10/10Internal combustion engine [ICE] based vehicles
    • Y02T10/30Use of alternative fuels, e.g. biofuels

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ588179A 2008-03-05 2009-03-05 Antiviral therapeutic agents comprising fused tricyclic compounds comprising a pyrrolo[1.2-f][1,2,4]triazine moiety NZ588179A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3405308P 2008-03-05 2008-03-05
US7937008P 2008-07-09 2008-07-09
PCT/US2009/036213 WO2009111653A2 (en) 2008-03-05 2009-03-05 Antiviral therapeutic agents

Publications (1)

Publication Number Publication Date
NZ588179A true NZ588179A (en) 2012-09-28

Family

ID=41054287

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ588179A NZ588179A (en) 2008-03-05 2009-03-05 Antiviral therapeutic agents comprising fused tricyclic compounds comprising a pyrrolo[1.2-f][1,2,4]triazine moiety

Country Status (16)

Country Link
US (2) US7994139B2 (https=)
EP (1) EP2265275A2 (https=)
JP (1) JP2011525171A (https=)
KR (1) KR20100137494A (https=)
CN (1) CN102834513A (https=)
AR (1) AR071745A1 (https=)
AU (1) AU2009221770A1 (https=)
BR (1) BRPI0910388A2 (https=)
CA (1) CA2717173A1 (https=)
EA (1) EA201070988A1 (https=)
IL (1) IL207826A0 (https=)
MX (1) MX2010009646A (https=)
NZ (1) NZ588179A (https=)
PE (1) PE20091727A1 (https=)
TW (1) TW200942243A (https=)
WO (1) WO2009111653A2 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009007333A (es) * 2007-01-12 2009-08-31 Biocryst Pharm Inc Analogos de nucleosidos antivirales.
HRP20120914T1 (hr) 2007-05-10 2012-12-31 Biocryst Pharmaceuticals, Inc. Spojevi tetrahidrofuro[3,4-d]dioksolana, namijenjeni upotrebi u lijeäśenju virusnih infekcija i raka
US20090247750A1 (en) * 2008-03-28 2009-10-01 Biocryst Pharmaceuticals, Inc. Process for preparing nucleoside analogs
HUE025528T2 (en) 2008-04-23 2016-05-30 Gilead Sciences Inc 1'-substituted carba-nucleoside analogs for antiviral treatment
WO2010002877A2 (en) * 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
MX2012003126A (es) 2009-09-21 2012-06-19 Gilead Sciences Inc Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos.
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
AU2011282241B2 (en) 2010-07-19 2015-07-30 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
DK2898885T3 (en) 2010-10-15 2018-02-05 Biocryst Pharm Inc PYRROLOPYRIMIDINE DERIVATIVES FOR USE IN TREATMENT OF VIRUS INFECTIONS
WO2013033093A1 (en) * 2011-08-29 2013-03-07 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
AR090699A1 (es) 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
US8906929B2 (en) * 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
CN105008369B (zh) * 2013-03-14 2017-07-11 百时美施贵宝公司 人类免疫缺陷病毒复制抑制剂
CN104946646B (zh) * 2014-03-25 2020-03-31 中国医学科学院基础医学研究所 用于预防和/或治疗埃博拉病毒性出血热的小核酸分子、dna分子、蛋白及应用
TWI687432B (zh) 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
DK3785717T3 (da) 2015-09-16 2022-03-21 Gilead Sciences Inc Fremgangsmåder til behandling af coronaviridae-infektioner
EP3222292A1 (en) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
JP7046015B2 (ja) 2016-03-06 2022-04-01 バイオクライスト ファーマシューティカルズ, インコーポレイテッド ジカウイルス感染の治療のための方法及び組成物
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
US10682368B2 (en) 2017-03-14 2020-06-16 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
CA3059777C (en) 2017-05-01 2023-02-21 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
CN111471056B (zh) * 2019-01-23 2021-07-02 成都先导药物开发股份有限公司 一种大环类免疫调节剂
JP2023512656A (ja) 2020-01-27 2023-03-28 ギリアード サイエンシーズ, インコーポレイテッド SARS CoV-2感染を治療するための方法
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
KR20220153619A (ko) 2020-03-12 2022-11-18 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오사이드의 제조 방법
CA3172483A1 (en) 2020-04-06 2021-10-14 Scott Ellis Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
PE20230618A1 (es) 2020-06-24 2023-04-14 Gilead Sciences Inc Analogos de nucleosido de 1'-ciano y usos de los mismos
IL300453A (en) 2020-08-27 2023-04-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1144373B1 (en) 1999-01-13 2005-10-19 Genentech, Inc. Serine protease inhibitors
JP2002279640A (ja) 2001-03-21 2002-09-27 Ricoh Co Ltd ウォブル検出回路とその装置
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
NZ546055A (en) * 2003-08-27 2010-05-28 Biota Scient Management Novel tricyclic nucleosides or nucleotides as therapeutic agents
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
AU2005302448B2 (en) 2004-10-29 2012-07-19 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
AR058419A1 (es) 2005-02-28 2008-02-06 Gilead Sciences Inc Compuestos de nucleosidos triciclicos para tratar infecciones virales
US7842672B2 (en) * 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
MX2009007333A (es) 2007-01-12 2009-08-31 Biocryst Pharm Inc Analogos de nucleosidos antivirales.
HRP20120914T1 (hr) 2007-05-10 2012-12-31 Biocryst Pharmaceuticals, Inc. Spojevi tetrahidrofuro[3,4-d]dioksolana, namijenjeni upotrebi u lijeäśenju virusnih infekcija i raka

Also Published As

Publication number Publication date
MX2010009646A (es) 2010-09-28
AU2009221770A1 (en) 2009-09-11
KR20100137494A (ko) 2010-12-30
IL207826A0 (en) 2010-12-30
CA2717173A1 (en) 2009-09-11
WO2009111653A2 (en) 2009-09-11
PE20091727A1 (es) 2009-12-04
CN102834513A (zh) 2012-12-19
US20120142617A1 (en) 2012-06-07
EA201070988A1 (ru) 2011-12-30
US20090227524A1 (en) 2009-09-10
TW200942243A (en) 2009-10-16
BRPI0910388A2 (pt) 2019-06-11
AR071745A1 (es) 2010-07-14
EP2265275A2 (en) 2010-12-29
US7994139B2 (en) 2011-08-09
JP2011525171A (ja) 2011-09-15
WO2009111653A3 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
NZ588179A (en) Antiviral therapeutic agents comprising fused tricyclic compounds comprising a pyrrolo[1.2-f][1,2,4]triazine moiety
NZ609146A (en) Modified 4’-nucleosides as antiviral agents
PH12021500040A1 (en) Bridged tricyclic carbamolypyridone compunds and their pharmaceutical use
MX2007004979A (es) Derivados de indol tetraciclicos como agentes antiviricos.
WO2007029029A3 (en) Tetracyclic indole derivatives as antiviral agents
WO2011041713A3 (en) Piperazinyl antiviral agents
IL198610A0 (en) Chemical compounds
WO2008147557A3 (en) Heteroaryl substituted thiazoles and their use as antiviral agents
EP2041159B8 (en) Macrocyclic compounds as antiviral agents
CL2011001906A1 (es) Compuestos derivados de ribosidos de tieno[3,4-d]pirimidin-7-ilo, y fosfatos de ribosidos; compuestos intermediarios; metodos de preparacion; metodo de tratamiento; composicion farmaceutica; y su uso para tratar una infeccion viral causada por un virus hepatitis c o un virus flaviridae.
PL1934243T3 (pl) Proces metatezy z zamknięciem pierścienia w zastosowaniu do wytwarzania peptydów makrocyklicznych
PH12015502237A1 (en) N- [ (2 ` r) -2 ` -deoxy-2 ` -fluoro-2 ` -methyl-p-phenyl-5 ` -uridylyl] -l-alanine 1-methylethyl ester and process for its production
JO2403B1 (en) Nickeloside derivatives antiviral
UA91255C2 (uk) Антивірусні нуклеозиди
WO2002100851A3 (en) Thiophene derivatives as antiviral agents for flavivirus infection
WO2005084192A3 (en) Novel 2’-c-methyl nucleoside derivatives
TW200621761A (en) Heterocyclic antiviral compounds
MX2010008148A (es) Métodos de tratamiento de infecciones virales.
MX2012007420A (es) Analogos para el tratamiento o prevencion de infecciones de flavivirus.
EA200970375A1 (ru) Соединения и способы лечения вируса гепатита с
WO2006033709A3 (en) Novel nucleoside derivatives
WO2010149598A3 (en) Heterocyclic antiviral compound
MX384745B (es) Proceso para la preparación de compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidina-2,7-diona 3-sustituidos.
IL193113A0 (en) Heterocyclic antiviral compounds
NZ603177A (en) Nucleoside cyclicphosphates

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 05 MAR 2016 BY CPA GLOBAL

Effective date: 20130129

LAPS Patent lapsed